Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved

Dow Jones

3小時前

Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.

The Danish company said Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity.

The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis.

Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones.

Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes.

Separately, the company said its board authorized a $400 million buyback.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2667699622"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667699622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667699622?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 06:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667699622","market":"fut","top_or_hot":-1,"title":"Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk. \n</p>\n<p>\n  The Danish company said  Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. \n</p>\n<p>\n  The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis. \n</p>\n<p>\n  Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones. \n</p>\n<p>\n  Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes. \n</p>\n<p>\n  Separately, the company said its board authorized a $400 million buyback. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-09-15 06:34</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk. \n</p>\n<p>\n  The Danish company said  Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. \n</p>\n<p>\n  The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis. \n</p>\n<p>\n  Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones. \n</p>\n<p>\n  Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes. \n</p>\n<p>\n  Separately, the company said its board authorized a $400 million buyback. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2667699622","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667699622","pubTimestamp":1789425240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk.The Danish company said  Monday it can develop, manufacture","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MEDI":"HARBOR HEALTH CARE ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","ASND":"Ascendis Pharma A/S","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4585":"ETF&股票定投概念"},"translate_title":"Ascendis Pharma 重新获得减肥技术权利；股份回购获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":0.9,"MEDI":0.6},"content_text":"Ascendis Pharma regained exclusive rights to develop its TransCon technology to treat obesity after ending its partnership with Novo Nordisk. \n\n\n  The Danish company said  Monday it can develop, manufacture and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. \n\n\n  The regaining of the rights follows a termination of the collaboration agreement between Ascendis and Novo Nordisk, which was announced in November 2024. Following termination, all licenses granted to Novo Nordisk, including once-monthly TransCon semaglutide, revert to Ascendis. \n\n\n  Neither party has any financial obligation to the other. In the original deal, Ascendis was eligible to receive up to $285 million in payments from upfront, development and regulatory milestones. \n\n\n  Ascendis plans to initiate multiple programs in both rare and large metabolic and cardiovascular indications. The new programs include advancing TransCon semaglutide as a potential treatment for obesity and Type 2 diabetes. \n\n\n  Separately, the company said its board authorized a $400 million buyback.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}